Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
200 JPY | -6.54% | +5.82% | -5.66% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.66% | 57.67M | - | ||
+16.25% | 122B | B+ | ||
+19.28% | 113B | B+ | ||
+18.95% | 26.49B | B | ||
-23.42% | 19.4B | B+ | ||
-19.03% | 16.24B | A- | ||
-19.88% | 15.4B | B | ||
-46.14% | 15.15B | A- | ||
+64.11% | 14.93B | C+ | ||
+4.68% | 13.52B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4893 Stock
- Ratings Noile-Immune Biotech Inc.